ミシガン州における自己免疫疾患の臨床試験
ミシガン州内の拠点で、自己免疫疾患に関する9件の研究が参加者を募集しています。
ミシガン州内の都市
公式研究テキスト（英語）
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Clinical Research Inst of MI, Saint Clair Shores
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07621809Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
- University of Michigan, Ann Arbor
被験者募集中観察研究
1 Month – 100 Years · 全性別 · 2026/09/24更新 · NCT00246857RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of Michigan - Accepting Young Adult and Juvenile Patients, Ann Arbor
被験者募集中第2/3相
6歳〜75歳 · 全性別 · 2026/09/17更新 · NCT06154252Daratumumab in Primary Antiphospholipid Syndrome
- University of Michigan, Ann Arbor
被験者募集中第1/2相
18歳〜65歳 · 全性別 · 2026/09/16更新 · NCT05671757RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- University of Michigan, Ann Arbor
被験者募集中第2/3相
18歳〜75歳 · 全性別 · 2026/08/17更新 · NCT06328777A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- University of Michigan, Ann Arbor
被験者募集中第3相
12歳以上 · 全性別 · 2026/08/06更新 · NCT06056297Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1026, Detroit
- Site Number - 1005, East Lansing
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/07/30更新 · NCT07039916A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Michigan, Ann Arbor
- Children's Hospital of Michigan, Detroit
- Henry Ford Health System, Detroit
- 他2件
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- Karmanos Cancer Institute, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/25更新 · NCT06626919ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。